BG00002-E (natalizumab high titer) ( DrugBank: Natalizumab )


1 disease
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica1

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,342 Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00516893
(ClinicalTrials.gov)
October 200614/8/2007Natalizumab High Titer Immunogenicity and SafetyA Multicenter, Open-Label Immunogenicity and Safety Study of Natalizumab High Titer Material (BG00002-E) in Subjects With Relapsing Forms of Multiple SclerosisMultiple SclerosisBiological: BG00002-E (natalizumab high titer)BiogenElan PharmaceuticalsCompleted18 Years55 YearsAll113Phase 2United States